Joseph F. Woody is currently the CEO of Avanos Medical, Inc., a healthcare company focused on advancing patient care. He took on this role in June 2017, succeeding Robert E. Abernathy. Woody has over 20 years of experience in the...

Joseph F. Woody is currently the CEO of Avanos Medical, Inc., a healthcare company focused on advancing patient care. He took on this role in June 2017, succeeding Robert E. Abernathy. Woody has over 20 years of experience in the healthcare field. Before he joined Avanos, he was the CEO of Acelity Holdings, a company known for advanced wound care, from 2015 to 2017. He also held leadership positions at Kinetic Concepts and Covidien, showing a solid background in managing healthcare companies. Under his leadership, Avanos aims to improve patient outcomes with innovative solutions. In 2020, Woody’s total compensation was around $2.4 million, with a big part coming from performance bonuses based on company metrics. His compensation package reflects a strong focus on rewarding performance and aligning with the company's goals. Interestingly, his stock awards did not vest in 2020 because performance metrics weren’t met, highlighting the pay-for-performance culture he operates in. As of 2020, he owns about 321,357 shares of Avanos, signaling confidence in the company's future.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Avanos Medical CEOs

A

Joseph F. Woody

Ex-CEO of Avanos Medical

Education

Not specified

Field of Expertise

Healthcare & Life Sciences - Healthcare

Sector of Economy

Healthcare

Born

January 1, 1966 - 59 years ago

CEO of Avanos Medical for

7 years 9 months (Jan 2017 - Oct 2024)

Previous Experience

Executive leadership in healthcare industry

Rivals

Competitors/colleagues of Joseph F. Woody

Holdings

See how much did Joseph F. Woody make over time.

As of 2020, Joseph F. Woody held approximately 321,357 shares in Avanos Medical, reflecting his significant stake in the company. This aligns his interests closely with those of shareholders. During his time as CEO, Woody's stock performance has seen ups...

As of 2020, Joseph F. Woody held approximately 321,357 shares in Avanos Medical, reflecting his significant stake in the company. This aligns his interests closely with those of shareholders. During his time as CEO, Woody's stock performance has seen ups and downs. His holdings indicate strong confidence in the company, despite fluctuations. In 2020, his stock-related income was impacted as no performance-based awards vested, showcasing the strict pay-for-performance expectations at Avanos. While bonuses have been substantial in previous years, 2020's lack of vested stock points to a year of challenges, potentially setting the stage for future recovery as performance improves. Understanding his investment showcases a commitment to long-term success.

Insider Trading

See recent insider trades of Joseph F. Woody.

AVNS

$2.62M

AVNS at $19.14/share

Mar 6, 2024

Received

AVNS

86,547 shares

AVNS

Mar 6, 2023

Received

AVNS

80,933 shares

AVNS

Mar 4, 2022

Received

AVNS

$2.66M

AVNS at $47.29/share

Mar 17, 2021

Received

AVNS

$2.67M

AVNS at $47.49/share

Mar 17, 2021

Received

AVNS

$2.81M

AVNS at $47.29/share

Mar 17, 2021

Received

AVNS

$3.98M

AVNS at $30.67/share

May 7, 2020

Received

AVNS

$139.83K

AVNS at $39.95/share

May 30, 2019

Purchase

AVNS

$151.73K

AVNS at $43.35/share

Nov 28, 2018

Purchase

Compensation History

See how much did Joseph F. Woody make over time.

In 2020, Joseph F. Woody's total compensation was approximately $2.4 million. This figure included a salary of about $938,897 and a significant annual cash bonus of $1.4 million, which was tied to performance metrics. He did not receive any stock grants or vested stocks that year due to unmet performance goals, emphasizing the company's focus on pay-for-performance. In previous years, his compensation was more favorable, reaching up to $6.2 million in total compensation when performance metrics were met. Woody's compensation package reflects a philosophy that aligns the interests of executives with those of the company and its shareholders. This method aims to foster an environment where leadership is directly linked to company success and growth.

Year

2020

Total Compensation

$2.42M

Salary

$938.90K

Board Justification

The compensation philosophy emphasizes pay-for-performance, aligning executive compensation with the company's financial and operational goals, and retaining key talent.

Bonus

$1.48M

Board Justification

The annual cash incentive payout for 2020 was based on performance metrics including Adjusted Net Sales, Adjusted EBITDA, and Strategic Initiatives, with a total payout percentage of 137% of the target payment amount.

Other

$0.00

Board Justification

No additional compensation was reported for 2020.

Restricted Stock

$0.00(0 N/A)

Board Justification

No performance-based restricted stock units (PRSUs) vested in 2020 due to performance metrics not being met.

Performance Metrics

Performance metrics included Adjusted Net Sales, Adjusted EBITDA, and Strategic Initiatives.

Other Avanos Medical CEOs

Here are other CEOs of Avanos Medical

Michael C. Greiner

CEO of Avanos Medical

October 2024 - Present